UMED Stock Overview
Unité de Fabrication des Médicaments S.A. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Unité de Fabrication des Médicaments S.A Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | د.ت7.05 |
| 52 Week High | د.ت7.57 |
| 52 Week Low | د.ت6.17 |
| Beta | 0.097 |
| 1 Month Change | -1.40% |
| 3 Month Change | -1.81% |
| 1 Year Change | -3.82% |
| 3 Year Change | -5.62% |
| 5 Year Change | -23.37% |
| Change since IPO | -32.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| UMED | TN Pharmaceuticals | TN Market | |
|---|---|---|---|
| 7D | -2.1% | 1.8% | -0.3% |
| 1Y | -3.8% | -7.3% | 9.4% |
Return vs Industry: UMED exceeded the TN Pharmaceuticals industry which returned -7.3% over the past year.
Return vs Market: UMED underperformed the TN Market which returned 9.4% over the past year.
Price Volatility
| UMED volatility | |
|---|---|
| UMED Average Weekly Movement | 1.8% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 2.8% |
| 10% most volatile stocks in TN Market | 4.5% |
| 10% least volatile stocks in TN Market | 1.8% |
Stable Share Price: UMED has not had significant price volatility in the past 3 months compared to the TN market.
Volatility Over Time: UMED's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | n/a | Ridha Charfeddine | www.unimed.com.tn |
Unité de Fabrication des Médicaments S.A. develops, manufactures, markets, and sells generic medicines under the UNIMED brand in Tunisia, Africa, Asia, and Europe. The company offers Opthalmic, ENT, and inhalation solutions, infusion solutions, injectable fluids and penicillin, and cephalosporin powders, as well as vaigtaine products in approximately 40 presentations for various therapeutic classes. It manufactures medicines for third party laboratories principals.
Unité de Fabrication des Médicaments S.A Fundamentals Summary
| UMED fundamental statistics | |
|---|---|
| Market cap | د.ت225.60m |
| Earnings (TTM) | د.ت6.43m |
| Revenue (TTM) | د.ت141.07m |
35.1x
P/E Ratio1.6x
P/S RatioIs UMED overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UMED income statement (TTM) | |
|---|---|
| Revenue | د.ت141.07m |
| Cost of Revenue | د.ت63.09m |
| Gross Profit | د.ت77.98m |
| Other Expenses | د.ت71.54m |
| Earnings | د.ت6.43m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.20 |
| Gross Margin | 55.27% |
| Net Profit Margin | 4.56% |
| Debt/Equity Ratio | 30.8% |
How did UMED perform over the long term?
See historical performance and comparisonDividends
6.7%
Current Dividend Yield161%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 08:26 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Unité de Fabrication des Médicaments S.A is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kais Kriaa | AlphaMena |
| Rim Ben Salah Gharbi | AlphaMena |
| Ghada Jendoubi | AlphaMena |